Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated ...

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

Metastatic prostate cancer can progress in different ways. In some men the disease advances rapidly, while other men have ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...

A multiomic approach for detecting clinically significant prostate cancer in seminal fluid: Results from a large multicenter clinical study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer ...

The longtime "SportsCenter" host plans to undergo surgery and is hoping to "normalize" the conversation about the illness.

Prostate cancer is the fourth most common cancer among men in India. Often symptomless in its early stages, it is highly ...